{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T11:26:36Z","timestamp":1774437996807,"version":"3.50.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,9,28]],"date-time":"2021-09-28T00:00:00Z","timestamp":1632787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,9,28]],"date-time":"2021-09-28T00:00:00Z","timestamp":1632787200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Royal College of Surgeons in Ireland - Bahrain","award":["134 \/ 02-Mar-2021"],"award-info":[{"award-number":["134 \/ 02-Mar-2021"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Glucose-6-phosphate dehydrogenase deficiency (G6PDd) is known to suppress the antioxidant system and is likely to aggravate severity of COVID-19, which results in a pro-oxidant response. This possible association has not been explored adequately in human studies. In this research, we report that the occurrence of non-invasive ventilation, intubation or death\u2014all of which are indicative of severe COVID-19, are not significantly different in hospitalized COVID-19 patients with and without G6PDd (4.6 vs. 6.4%, <jats:italic>p<\/jats:italic>\u2009=\u20090.33). The likelihood of developing any of these severe outcomes were slightly lower in patients with G6PDd after accounting for age, nationality, presence of comorbidities and drug interventions (Odds ratio 0.40, 95% confidence intervals 0.142, 1.148). Further investigation that extends to both, hospitalized and non-hospitalized COVID-19 patients, is warranted to study this potential association.<\/jats:p>","DOI":"10.1038\/s41598-021-98712-3","type":"journal-article","created":{"date-parts":[[2021,9,28]],"date-time":"2021-09-28T10:03:06Z","timestamp":1632823386000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Is glucose-6-phosphatase dehydrogenase deficiency associated with severe outcomes in hospitalized COVID-19 patients?"],"prefix":"10.1038","volume":"11","author":[{"given":"Nitya","family":"Kumar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"AbdulKarim","family":"AbdulRahman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdulla Ismaeel","family":"AlAwadhi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manaf","family":"AlQahtani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,9,28]]},"reference":[{"issue":"11","key":"98712_CR1","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1182\/blood.2019000944","volume":"136","author":"L Luzzatto","year":"2020","unstructured":"Luzzatto, L., Ally, M. & Notaro, R. Glucose-6-phosphate dehydrogenase deficiency. Blood 136(11), 1225\u20131240. https:\/\/doi.org\/10.1182\/blood.2019000944 (2020).","journal-title":"Blood"},{"issue":"3","key":"98712_CR2","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.bcmd.2008.12.005","volume":"42","author":"ET Nkhoma","year":"2009","unstructured":"Nkhoma, E. T., Poole, C., Vannappagari, V., Hall, S. A. & Beutler, E. The global prevalence of glucose-6-phosphate dehydrogenase deficiency: A systematic review and meta-analysis. Blood Cells Mol. Dis.  42(3), 267\u2013278. https:\/\/doi.org\/10.1016\/j.bcmd.2008.12.005 (2009).","journal-title":"Blood Cells Mol. Dis."},{"key":"98712_CR3","first-page":"1","volume":"24","author":"HC Yang","year":"2020","unstructured":"Yang, H. C., Ma, T. H., Tjong, W. Y., Stern, A. & Chiu, D. T. G6PD deficiency, redox homeostasis, and viral infections: implications for SARS-CoV-2 (COVID-19). Free Radic. Res. 24, 1\u20131 (2020).","journal-title":"Free Radic. Res."},{"key":"98712_CR4","doi-asserted-by":"publisher","first-page":"584112","DOI":"10.3389\/fmed.2020.584112","volume":"7","author":"Y Buinitskaya","year":"2020","unstructured":"Buinitskaya, Y., Gurinovich, R., Wlodaver, C. G. & Kastsiuchenka, S. Centrality of G6PD in COVID-19: the biochemical rationale and clinical implications. Front. Med. (Lausanne) 7, 584112. https:\/\/doi.org\/10.3389\/fmed.2020.584112 (2020).","journal-title":"Front. Med. (Lausanne)"},{"issue":"6","key":"98712_CR5","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1086\/528377","volume":"197","author":"YH Wu","year":"2008","unstructured":"Wu, Y. H. et al. Glucose-6-phosphate dehydrogenase deficiency enhances human coronavirus 229E infection. J. Infect. Dis. 197(6), 812\u2013816. https:\/\/doi.org\/10.1086\/528377 (2008).","journal-title":"J. Infect. Dis."},{"issue":"11","key":"98712_CR6","first-page":"3320","volume":"4","author":"R Littera","year":"2020","unstructured":"Littera, R. et al. Human leukocyte antigen complex and other immunogenetic and clinical factors influence susceptibility or protection to SARS-CoV-2 infection and severity of the disease course. The Sardinian experience. Front. Immunol. 4(11), 3320 (2020).","journal-title":"Front. Immunol."},{"issue":"1","key":"98712_CR7","first-page":"18","volume":"32","author":"AS Al","year":"2010","unstructured":"Al, A. S. Frequency of G6PD deficiency among Bahraini students: A ten years\u2019 study. Bahrain Med. Bull. 32(1), 18\u201321 (2010).","journal-title":"Bahrain Med. Bull."},{"issue":"2","key":"98712_CR8","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1093\/tropej\/44.2.70","volume":"44","author":"AM Mohammad","year":"1998","unstructured":"Mohammad, A. M., Ardatl, K. O. & Bajakian, K. M. Sickle cell disease in Bahrain: coexistence and interaction with glucose-6-phosphate dehydrogenase (G6PD) deficiency. J. Trop. Pediatr. 44(2), 70\u201372. https:\/\/doi.org\/10.1093\/tropej\/44.2.70 (1998).","journal-title":"J. Trop. Pediatr."},{"issue":"3","key":"98712_CR9","first-page":"120","volume":"9","author":"GP Bhagwat","year":"1987","unstructured":"Bhagwat, G. P. & Bapat, J. P. Glucose-6-phosphate dehydrogenase deficiency in Bahraini blood donors. Bahrain Med. Bull. 9(3), 120\u2013122 (1987).","journal-title":"Bahrain Med. Bull."},{"key":"98712_CR10","unstructured":"The official website for the latest health developments, Kingdom of Bahrain. https:\/\/healthalert.gov.bh\/en\/category\/daily-covid-19-report. Accessed 22 Dec 2020 (2020)."},{"key":"98712_CR11","doi-asserted-by":"publisher","first-page":"458","DOI":"10.15585\/mmwr.mm6915e3","volume":"69","author":"S Garg","year":"2020","unstructured":"Garg, S. et al. Hospitalization rates and characteristics of patients hospitalized with laboratory-confirmed coronavirus disease 2019\u2014COVID-NET, 14 States, March 1\u201330, 2020. MMWR Morb. Mortal. Wkly. Rep. 69, 458\u2013464. https:\/\/doi.org\/10.15585\/mmwr.mm6915e3 (2020).","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"98712_CR12","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1001\/jama.2020.6775","volume":"323","author":"S Richardson","year":"2020","unstructured":"Richardson, S. et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. JAMA 323, 2052 (2020).","journal-title":"JAMA"},{"key":"98712_CR13","doi-asserted-by":"publisher","first-page":"108263","DOI":"10.1016\/j.diabres.2020.108263","volume":"165","author":"A Alkundi","year":"2020","unstructured":"Alkundi, A., Mahmoud, I., Musa, A., Naveed, S. & Alshawwaf, M. Clinical characteristics and outcomes of COVID-19 hospitalized patients with diabetes in the United Kingdom: A retrospective single centre study. Diabetes Res. Clin. Pract. 165, 108263 (2020).","journal-title":"Diabetes Res. Clin. Pract."},{"key":"98712_CR14","doi-asserted-by":"publisher","DOI":"10.1002\/jha2.170","author":"A Abdulrahman","year":"2021","unstructured":"Abdulrahman, A. et al. Is sickle cell disease a risk factor for severe COVID-19: a multicenter national retrospective cohort. eJHAEM https:\/\/doi.org\/10.1002\/jha2.170 (2021).","journal-title":"eJHAEM"},{"issue":"10","key":"98712_CR15","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.3201\/eid2610.202792","volume":"26","author":"JA Panepinto","year":"2020","unstructured":"Panepinto, J. A. et al. Coronavirus disease among persons with sickle cell disease, United States, March 20\u2013May 21, 2020. Emerg. Infect. Dis. 26(10), 2473 (2020).","journal-title":"Emerg. Infect. Dis."},{"issue":"8","key":"98712_CR16","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1007\/s00125-020-05180-x","volume":"63","author":"B Cariou","year":"2020","unstructured":"Cariou, B. et al. Phenotypic characteristics and prognosis of inpatients with COVID-19 and diabetes: the CORONADO study. Diabetologia 63(8), 1500. https:\/\/doi.org\/10.1007\/s00125-020-05180-x (2020).","journal-title":"Diabetologia"},{"key":"98712_CR17","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1136\/thorax.2003.012658","volume":"59","author":"CM Chu","year":"2004","unstructured":"Chu, C. M. et al. Role of lopinavir\/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax 59, 252\u2013256 (2004).","journal-title":"Thorax"},{"key":"98712_CR18","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1016\/j.ijantimicag.2014.07.026","volume":"44","author":"N Spanakis","year":"2014","unstructured":"Spanakis, N. et al. Virological and serological analysis of a recent Middle East respiratory syndrome coronavirus infection case on a triple combination antiviral regimen. Int. J. Antimicrob. Agents 44, 528\u2013532 (2014).","journal-title":"Int. J. Antimicrob. Agents"},{"key":"98712_CR19","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1016\/S1473-3099(14)70920-X","volume":"14","author":"AS Omrani","year":"2014","unstructured":"Omrani, A. S. et al. Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: A retrospective cohort study. Lancet Infect. Dis. 14, 1090\u20131095. https:\/\/doi.org\/10.1016\/S1473-3099(14)70920-X (2014).","journal-title":"Lancet Infect. Dis."},{"key":"98712_CR20","first-page":"2","volume":"1","author":"P Horby","year":"2020","unstructured":"Horby, P. et al. Effect of hydroxychloroquine in hospitalized patients with covid-19. N. Engl. J. Med. 1, 2 (2020).","journal-title":"N. Engl. J. Med."},{"key":"98712_CR21","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-021-00397-8","author":"A Abdulrahman","year":"2021","unstructured":"Abdulrahman, A. et al. The efficacy and safety of hydroxychloroquine in patients with COVID-19: a multicenter national retrospective cohort. Infect. Dis. Ther. https:\/\/doi.org\/10.1007\/s40121-021-00397-8 (2021).","journal-title":"Infect. Dis. Ther."},{"key":"98712_CR22","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1056\/NEJMoa2001282","volume":"382","author":"B Cao","year":"2020","unstructured":"Cao, B. et al. A trial of lopinavir\u2013ritonavir in adults hospitalized with severe Covid-19. N. Engl. J. Med. 382, 1787\u20131799 (2020).","journal-title":"N. Engl. J. Med."},{"issue":"10259","key":"98712_CR23","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1016\/S0140-6736(20)32013-4","volume":"396","author":"PW Horby","year":"2020","unstructured":"Horby, P. W. et al. Lopinavir\u2013ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet 396(10259), 1345\u20131352 (2020).","journal-title":"Lancet"},{"key":"98712_CR24","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/S0140-6736(21)00149-5","volume":"397","author":"E Abaleke","year":"2021","unstructured":"Abaleke, E. et al. Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet 397, 605\u2013612 (2021).","journal-title":"Lancet"},{"issue":"3","key":"98712_CR25","doi-asserted-by":"publisher","first-page":"106114","DOI":"10.1016\/j.ijantimicag.2020.106114","volume":"56","author":"S Tong","year":"2020","unstructured":"Tong, S. et al. Ribavirin therapy for severe COVID-19: a retrospective cohort study. Int. J. Antimicrob. Agents. 56(3), 106114. https:\/\/doi.org\/10.1016\/j.ijantimicag.2020.106114 (2020).","journal-title":"Int. J. Antimicrob. Agents."},{"key":"98712_CR26","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1056\/NEJMoa2021436","volume":"384","author":"RECOVERY Collaborative Group","year":"2020","unstructured":"RECOVERY Collaborative Group. Dexamethasone in hospitalized patients with Covid-19\u2014preliminary report. N. Engl. J. Med. 384, 693\u2013704 (2020).","journal-title":"N. Engl. J. Med."},{"issue":"24","key":"98712_CR27","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.1001\/jama.2020.8630","volume":"323","author":"ES Rosenberg","year":"2020","unstructured":"Rosenberg, E. S. et al. Association of treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in New York State. JAMA 323(24), 2493\u20132502 (2020).","journal-title":"JAMA"},{"issue":"22","key":"98712_CR28","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.1093\/eurheartj\/ehaa433","volume":"41","author":"C Gao","year":"2020","unstructured":"Gao, C. et al. Association of hypertension and antihypertensive treatment with COVID-19 mortality: A retrospective observational study. Eur. Heart J. 41(22), 2058\u20132066. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa433 (2020).","journal-title":"Eur. Heart J."},{"issue":"6","key":"98712_CR29","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1007\/s10900-020-00920-x","volume":"45","author":"FM Noor","year":"2020","unstructured":"Noor, F. M. & Islam, M. M. Prevalence and associated risk factors of mortality among COVID-19 patients: A meta-analysis. J. Commun. Health 45(6), 1270\u20131282 (2020).","journal-title":"J. Commun. Health"},{"issue":"1","key":"98712_CR30","doi-asserted-by":"publisher","first-page":"105949","DOI":"10.1016\/j.ijantimicag.2020.105949","volume":"56","author":"P Gautret","year":"2020","unstructured":"Gautret, P. et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: Results of an open-label non-randomized clinical trial. Int. J. Antimicrob. Agents 56(1), 105949 (2020).","journal-title":"Int. J. Antimicrob. Agents"},{"issue":"5","key":"98712_CR31","doi-asserted-by":"publisher","first-page":"2000524","DOI":"10.1183\/13993003.00524-2020","volume":"55","author":"RH Du","year":"2020","unstructured":"Du, R. H. et al. Predictors of mortality for patients with COVID-19 pneumonia caused by SARS-CoV-2: A prospective cohort study. Eur. Respir. J. 55(5), 2000524. https:\/\/doi.org\/10.1183\/13993003.00524-2020 (2020).","journal-title":"Eur. Respir. J."},{"key":"98712_CR32","doi-asserted-by":"publisher","DOI":"10.1002\/oby.22831","author":"A Simonnet","year":"2020","unstructured":"Simonnet, A. et al. High prevalence of obesity in severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) requiring invasive mechanical ventilation. Obesity https:\/\/doi.org\/10.1002\/oby.22831 (2020).","journal-title":"Obesity"},{"key":"98712_CR33","doi-asserted-by":"publisher","DOI":"10.1017\/S095026882000117X","author":"J Zhang","year":"2020","unstructured":"Zhang, J. et al. Associations of hypertension with the severity and fatality of SARS-CoV-2 infection: a meta-analysis. Epidemiol. Infect. https:\/\/doi.org\/10.1017\/S095026882000117X (2020).","journal-title":"Epidemiol. Infect."},{"key":"98712_CR34","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1038\/s41586-020-2521-4","volume":"584","author":"EJ Williamson","year":"2020","unstructured":"Williamson, E. J. et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature 584, 430\u2013436. https:\/\/doi.org\/10.1038\/s41586-020-2521-4 (2020).","journal-title":"Nature"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-98712-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-98712-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-98712-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T15:53:26Z","timestamp":1670082806000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-98712-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,28]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["98712"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-98712-3","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,28]]},"assertion":[{"value":"24 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"19213"}}